PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

Senan, Suresh; Brade, Anthony; Wang, Lu Hua; Vansteenkiste, Johan; Dakhil, Shaker R.; Biesma, Bonne; Aguillo, Maite Martinez; Aerts, Joachim; Govindan, Ramaswamy; Rubio-Viqueira, Belén; Lewanski, Conrad; Gandara, David R.; Choy, Hak; Mok, Tony; Hossain, Anwar; Iscoe, Neill; Treat, Joseph; Koustenis, Andrew; Antonio, Belén San; Chouaki, N.; Vokes, Everett E.

doi:10.1200/jco.2015.64.8824

Cited by 388 publications

(308 citation statements)

References 30 publications

Supporting

Mentioning

274

Contrasting

Unclassified

Order By: Relevance

“…The preliminary results showed that despite the high anticancer activity of pemetrexed relative to the other drugs, there were no differences in mOS (26.8 months vs. 25 months), and 3-year survival rates (40% vs. 37%) between the pemetrexed plus cisplatin group and the etoposide plus cisplatin group. The toxicity profile differed in the two groups, and a significantly lower incidence of drug-related grade ≥ 3 AEs was found in the pemetrexed group compared with the etoposide group (Senan et al 2015). An early study revealed that combination treatment with cisplatin and 5-FU may cause synergistic cytotoxicity in NSCLC cells (Tsai et al 1993).…”

Section: Discussionmentioning

confidence: 92%

Meta-analysis Exploring the Effectiveness of S-1-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

Sun

Zhang

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

S-1 is a new oral fluoropyrimidine formulation that comprises tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate. S-1 is designed to enhance antitumor activity and to reduce gastrointestinal toxicity. Several studies have demonstrated that both S-1 monotherapy and S-1 combination regimens showed encouraging efficacies and mild toxicities in the treatment of lung squamous cell carcinoma and adenocarcinoma. However, it is unclear whether S-1 can be used as standard care in advanced non-small cell lung cancer (NSCLC). The purpose of this meta-analysis was to assess the efficacy and safety of S-1-based chemotherapy, compared with standard chemotherapy, in patients with locally advanced or metastatic NSCLC. Thirteen randomized controlled trials (RCTs) involving 2,134 patients with a similar ratio of different pathological types were included. In first-line or second-line chemotherapy, compared with standard chemotherapy, S-1-based chemotherapy showed similar efficacy in terms of median overall survival (mOS), median progression free survival (mPFS), and objective response rate (ORR) (all P > 0.1), and significantly reduced the incidence of grade ≥ 3 hematological toxicities. In patients with locally advanced NSCLC receiving concurrent chemoradiotherapy, compared with standard chemoradiotherapy, significantly improved survival in the S-1-based chemotherapy was noted in terms of mOS and mPFS (risk radio [RR] = 1.289, P = 0.009; RR = 1.289, P = 0.000, respectively) with lower incidence of grade ≥ 3 neutropenia (RR = 0.453, P = 0.000). The present meta-analysis demonstrates that S-1-based chemotherapy shows similar benefits in advanced NSCLC and improves survival in locally advanced NSCLC, compared with standard treatment.

show abstract

Section: Discussionmentioning

confidence: 92%

Meta-analysis Exploring the Effectiveness of S-1-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

Sun

Zhang

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Unresectable disease should preferentially be treated with concomitant chemo-radiotherapy (cCTRT), the most commonly used regimen being cisplatin with etoposide. Randomized trials testing modern platinum-based doublets, such as cisplatin plus pemetrexed and cisplatin plus vinorelbine, have failed to demonstrate superiority over that doublet, even though the toxicity profile appeared to be better with new agents 30,31 . …”

Section: Pharmacological Treatments Early Stagesmentioning

confidence: 99%

Lung Cancer Management: where are we in 2017?

Scagliotti¹,

Bironzo²,

Rosell³

2021

BRN

View full text Add to dashboard Cite

“…Currently, the clinical outcomes are still unsatisfactory, and the 5-year survival rate of is approximately 20%. In recent published studies, attempts to improvement of the radiation dose (RTOG 0617) and use of a new generation of chemotherapy regimen (PROCLAIM) failed to demonstrate survival benefits compared with concurrent platinum-based doublet chemoradiotherapy conventionally used in clinical practice (47,48). Uncertainties resulted from high treatment-related toxicities and poor completion rates of chemoradiotherapy in these trials should be rethink profoundly in future studies, and further improvement in locally advanced NSCLC will require the development of more effective combined modality therapies with low toxicities.…”

Section: Management Of Local Advanced Nsclc With Tki and Radiotherapymentioning

confidence: 99%

Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy—opportunities and challenges

Xia

Zhang

2017

J. Thorac. Dis.

View full text Add to dashboard Cite

In recent years, the treatment of advanced non-small cell lung cancer (NSCLC) was greatly promoted by the discovery of oncogenic drivers and the development of targeted therapies specific for these drivers. Somatic mutations in epidermal growth factor receptor (EGFR) are the most common type in patients with NSCLC. Small-molecule tyrosine kinase inhibitor (TKI) targeting EGFR produced relatively high response rate and long duration with acceptable toxicity profile. Also, the life expectancy in patients with active EGFR mutation has been significantly prolonged than the past. Additionally, evolution of advanced imaging and radiation techniques has expanded the indications for radiotherapy in complex clinical situation. All of those factors contributed to the widely use of radiotherapy for advanced NSCLC treated with TKI therapy. In this review, we will discuss how to integrate radiotherapy into the comprehensive treatment of patients with TKI therapy in order to maximize the therapeutics effect.

show abstract

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

Abstract: Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexed was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous non-small-cell lung cancer.

Cited by 388 publications

References 30 publications

Meta-analysis Exploring the Effectiveness of S-1-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

Meta-analysis Exploring the Effectiveness of S-1-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

Lung Cancer Management: where are we in 2017?

Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy—opportunities and challenges

Contact Info

Product

Resources

About